IL-6 blockers in systemic onset juvenile idiopathic arthritis

被引：16
|
作者：
Barone, Patrizia [1 ]
Pignataro, Rossana [1 ]
Garozzo, Maria Teresa [1 ]
Leonardi, Salvatore [1 ]
机构：
[1] Univ Catania, Dept Clin & Expt Med, I-95124 Catania, Italy
来源：
IMMUNOTHERAPY | 2016年 / 8卷 / 01期
关键词：
interleukin; 6; systemic onset idiopathic arthritis; tocilizumab; INTERLEUKIN (IL)-6; SIGNAL TRANSDUCER; DOUBLE-BLIND; PHASE-II; GENE; EFFICACY; SAFETY; TOCILIZUMAB; ASSOCIATION; EXPRESSION;
D O I：
10.2217/imt.15.104
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
IL-6 has a key role in the pathogenesis, clinical manifestations and activity of Systemic Onset Idiopathic Arthritis (sJIA). Tocilizumab (TCZ), the first humanized antihuman IL-6 receptor antibody, inhibits the activity of IL-6. In this review, we summarize the main studies performed, to date, about the use of TCZ in children affected by sJIA refractory to conventional treatment. Nowadays TCZ can be used, alone or in association with Metotrexate, in children older than 2 years. Its use in children younger than 2 years is being investigated. Further study about its use in sJIA and other type of idiopathic arthritis should be done.
引用
收藏
页码：79 / 87
页数：9
相关论文
共 50 条
  • [1] IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
    Yokota, S
    Miyamae, T
    Imagawa, T
    Mori, M
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S22 - S23
  • [2] IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
    S Yokota
    T Miyamae
    T Imagawa
    M Mori
    Arthritis Res Ther, 5
  • [3] Systemic onset juvenile idiopathic arthritis
    Frosch, M.
    Holzinger, D.
    Roth, J.
    MONATSSCHRIFT KINDERHEILKUNDE, 2012, 160 (03) : 217 - +
  • [4] THE USE OF A COMBINATION OF IL-1 AND IL-6 INHIBITION IN THE MANAGEMENT OF SEVERE, AGGRESSIVE, EROSIVE, SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
    Lee, Martin
    Nicholl, Karl
    Campbell, Ian
    RHEUMATOLOGY, 2016, 55 : 157 - 157
  • [5] A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis
    Keul, R
    Heinrich, PC
    Muller-Newen, G
    Muller, K
    Woo, P
    CYTOKINE, 1998, 10 (09) : 729 - 734
  • [6] Effect of IL-6 on IGF binding protein-3: A study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis
    De Benedetti, F
    Meazza, C
    Oliveri, M
    Pignatti, P
    Vivarelli, M
    Alonzi, T
    Fattori, E
    Garrone, S
    Barreca, A
    Martini, A
    ENDOCRINOLOGY, 2001, 142 (11) : 4818 - 4826
  • [7] Proof of principle of the efficacy of IL-6 receptor blockade in severe systemic juvenile idiopathic arthritis (SJIA)
    Woo, P
    Wilkinson, N
    Prieur, A
    Southwood, T
    Leone, V
    Livermore, P
    Wythe, H
    Thomson, D
    Kishimoto, T
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 84 - 84
  • [8] IL-6 AND ALLELIC POLYMORPHISM OF ITS GENE IN JUVENILE IDIOPATHIC ARTHRITIS
    Artsymovych, Agar
    Oshlianska, Olena
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1933 - 1933
  • [9] Leflunomide in systemic onset juvenile idiopathic arthritis
    Afsana Jahan
    Vivek Dewan
    Tribhuvan Pal Yadav
    Indian Pediatrics, 2012, 49 : 750 - 752
  • [10] Systemic-onset juvenile idiopathic arthritis
    Cimaz, Rolando
    AUTOIMMUNITY REVIEWS, 2016, 15 (09) : 931 - 934
12345